Health and Healthcare

Amgen : AMGN

All Amgen Articles

707 Articles

Jon C. Ogg | Aug 15, 2018 at 11:50 AM EDT

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors.…

Chris Lange | Aug 10, 2018 at 8:45 AM EDT

Why Have Short Sellers Backed Off Major Biotechs?

The July 31 short interest data have been compared with the previous report, and short interest in most of the…

Jon C. Ogg | Jul 30, 2018 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Ally, Amgen, AT&T, BP, Chesapeake Energy, Expedia, NOV, Square, Synchrony, Twitter and More

The top analyst upgrades, downgrades and other research calls from Monday includes Ally Financial, Amgen, AT&T, BP, Chesapeake Energy, Expedia,…

Chris Lange | Jul 25, 2018 at 7:10 AM EDT

Major Biotechs See a Rising Tide of Short Interest

The July 13 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jul 22, 2018 at 10:25 AM EDT

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

24/7 Wall St. has put together a preview of AbbVie, Eli Lilly, Gilead Sciences and some of the other, larger…

Chris Lange | Jul 12, 2018 at 8:21 AM EDT

Short Sellers Back Off Major Biotechs

The June 29 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jun 27, 2018 at 9:00 AM EDT

Short Sellers Run for Cover From Major Biotechs

The June 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jun 12, 2018 at 10:54 AM EDT

Short Sellers Up the Ante For Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data…

Lee Jackson | Jun 1, 2018 at 10:30 AM EDT

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

It’s no surprise that it was only a matter of time before the usage and storage of big data and…

Chris Lange | May 25, 2018 at 9:40 AM EDT

Short Interest Remains Mixed in Major Biotechs

The May 15 short interest data have been compared with the previous report, and short interest moves in the selected…

Chris Lange | May 22, 2018 at 11:40 AM EDT

Amgen Wins Another FDA Approval

Amgen shares made a slight gain on Tuesday after it was announced that the FDA approved its treatment of glucocorticoid-induced…

Trey Thoelcke | May 18, 2018 at 8:00 AM EDT

Amgen’s Novel Migraine Treatment Gets Key Approval

Amgen shares saw a nice bump after the FDA on Thursday approved its preventive treatment of migraine in adults.

Chris Lange | May 10, 2018 at 10:40 AM EDT

Big Biotechs Scare Off Short Sellers

The April 30 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | May 5, 2018 at 8:40 AM EDT

The Top Biopharma Catalysts Coming in May

Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates…

Chris Lange | Apr 25, 2018 at 8:40 AM EDT

Major Biotechs Face Rising Tide of Short Interest

The April 13 short interest data have been compared with the previous report, and short interest in most of the…

1 … 15 16 17 18 19 … 48

Amgen : AMGN

All Amgen Articles

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

Why Have Short Sellers Backed Off Major Biotechs?

Top Analyst Upgrades and Downgrades: Ally, Amgen, AT&T, BP, Chesapeake Energy, Expedia, NOV, Square, Synchrony, Twitter and More

Major Biotechs See a Rising Tide of Short Interest

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

Short Sellers Back Off Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Short Sellers Up the Ante For Major Biotechs

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

Short Interest Remains Mixed in Major Biotechs

Amgen Wins Another FDA Approval

Amgen’s Novel Migraine Treatment Gets Key Approval

Big Biotechs Scare Off Short Sellers

The Top Biopharma Catalysts Coming in May

Major Biotechs Face Rising Tide of Short Interest

This 15-Minute Task Is All You Need to Know What Social Security Benefit to Expect

The 401(k) Vesting Cliff That Cost One Worker $74,000 Before Age 60

A Caller’s Dad Turned $22,000 Into $1 Million on a Single Stock. Now the Family Faces a $150,000 Tax Decision

This 15-Minute Task Is All You Need to Know What Social Security Benefit to Expect

The 401(k) Vesting Cliff That Cost One Worker $74,000 Before Age 60

This 15-Minute Task Is All You Need to Know What Social Security Benefit to Expect

The 401(k) Vesting Cliff That Cost One Worker $74,000 Before Age 60

Amgen : AMGN

All Amgen Articles

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

Why Have Short Sellers Backed Off Major Biotechs?

Top Analyst Upgrades and Downgrades: Ally, Amgen, AT&T, BP, Chesapeake Energy, Expedia, NOV, Square, Synchrony, Twitter and More

Major Biotechs See a Rising Tide of Short Interest

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

Short Sellers Back Off Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Short Sellers Up the Ante For Major Biotechs

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

Short Interest Remains Mixed in Major Biotechs

Amgen Wins Another FDA Approval

Amgen’s Novel Migraine Treatment Gets Key Approval

Big Biotechs Scare Off Short Sellers

The Top Biopharma Catalysts Coming in May

Major Biotechs Face Rising Tide of Short Interest

This 15-Minute Task Is All You Need to Know What Social Security Benefit to Expect

The 401(k) Vesting Cliff That Cost One Worker $74,000 Before Age 60

A Caller’s Dad Turned $22,000 Into $1 Million on a Single Stock. Now the Family Faces a $150,000 Tax Decision

Featured Reads

This 15-Minute Task Is All You Need to Know What Social Security Benefit to Expect

The 401(k) Vesting Cliff That Cost One Worker $74,000 Before Age 60